Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)
Hisashi Hidaka, Namiki Izumi, Takeshi Aramaki, Masafumi Ikeda, Yoshitaka Inaba, Kazuho Imanaka, Takuji Okusaka, Susumu Kanazawa, Shuichi Kaneko, Shinichi Kora, Hiroya Saito, Junji Furuse, Osamu Matsui, Tatsuya Yamashita, Osamu Yokosuka, Satoshi Morita, Hitoshi Arioka, Masatoshi Kudo, Yasuaki Arai (2019). Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). , 36(6), DOI: https://doi.org/10.1007/s12032-019-1272-2.
Article21 days agoOrantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Masatoshi Kudo, Ann‐Lii Cheng, Joong‐Won Park, Jae Hyung Park, Po‐Chin Liang, Hisashi Hidaka, Namiki Izumi, Jeong Heo, Youn Jae Lee, I‐Shyan Sheen, Chang‐Fang Chiu, Hitoshi Arioka, Satoshi Morita, Yasuaki Arai (2017). Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. , 3(1), DOI: https://doi.org/10.1016/s2468-1253(17)30290-x.
Article21 days agoLusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures
Hisashi Hidaka, Masayuki Kurosaki, Hironori Tanaka, Masatoshi Kudo, Seigo Abiru, Takumi Igura, Toru Ishikawa, Masataka Seike, Takayuki Katsube, Toshimitsu Ochiai, Kazuhiro Kimura, Takahiro Fukuhara, Takeshi Kano, Tsutae Den Nagata, Katsuaki Tanaka, Mineo Kurokawa, Kazuhide Yamamoto, Yukio Osaki, Namiki Izumi, Michio Imawari (2018). Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures. , 17(6), DOI: https://doi.org/10.1016/j.cgh.2018.11.047.
Article21 days agoPhase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients
Won Young Tak, Baek‐Yeol Ryoo, Ho Yeong Lim, Do Young Kim, Takuji Okusaka, Masafumi Ikeda, Hisashi Hidaka, Jong-Eun Yeon, Eishiro Mizukoshi, Manabu Morimoto, Myung Ah Lee, Kohichiroh Yasui, Yasunori Kawaguchi, Jeong Heo, Sojiro Morita, Tae‐You Kim, Junji Furuse, Kazuhiro Katayama, Takeshi Aramaki, Rina Hara, Takuya Kimura, Osamu Nakamura, Masatoshi Kudo (2018). Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. , 36(6), DOI: https://doi.org/10.1007/s10637-018-0658-x.
Article21 days agoS-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial
Masatoshi Kudo, Michihisa Moriguchi, Kazushi Numata, Hisashi Hidaka, Hironori Tanaka, Masafumi Ikeda, Seiji Kawazoe, Shinichi Ohkawa, Yozo Sato, Shuichi Kaneko, Junji Furuse, Madoka Takeuchi, Xuemin Fang, Yoshito Date, Masahiro Takeuchi, Takuji Okusaka, Masatoshi Kudo (2017). S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. , 2(6), DOI: https://doi.org/10.1016/s2468-1253(17)30072-9.
Article21 days ago